{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:27:26Z","timestamp":1786976846052,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Optimizing consolidation treatment in transplant\u2010eligible newly diagnosed multiple myeloma patients in order to improve efficacy and bone\u2010related outcomes is intriguing. We conducted an open\u2010label, prospective study evaluating the efficacy and safety of bortezomib and lenalidomide (VR) consolidation after ASCT, in the absence of dexamethasone and bisphosphonates. Fifty\u2010nine patients, who received bortezomib\u2010based induction, were given 4 cycles of VR starting on day 100 post\u2010ASCT. After ASCT, 58% of patients improved their response status, while following VR consolidation 39% further deepened their response; stringent complete response rates increased to 51% after VR from 24% post\u2010ASCT. VR consolidation resulted in a significant reduction of soluble receptor activator of nuclear factor\u2010\u03baB ligand\/osteoprotegerin ratio and sclerostin circulating levels, which was more pronounced among patients achieving very good partial response or better. After a median follow\u2010up of 62\u2009months, no skeletal\u2010related events (SREs) were observed, despite the lack of bisphosphonates administration. The median TTP after ASCT was 37\u2009months, while median overall survival (OS) has not been reached yet; the probability of 4\u2010 and 5\u2010year OS was 81% and 64%, respectively. In conclusion, VR consolidation is an effective, dexamethasone\u2010 and bisphosphonate\u2010free approach, which offers long OS with improvements on bone metabolism and no SREs.<\/jats:p>","DOI":"10.1002\/ajh.25392","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T02:34:22Z","timestamp":1545964462000},"page":"400-407","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis\u2010Stathopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[{"name":"Department of Hematology 251 General Air\u2010Force Hospital  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[{"name":"Department of Medical Research 251 General Air\u2010Force Hospital  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis\u2010Papaiakovou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6179-2772","authenticated-orcid":false,"given":"Ioannis P.","family":"Trougakos","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Biophysics, Faculty of Biology National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.174573"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq370"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1283"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4"},{"key":"e_1_2_8_8_1","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","author":"Raje NS","year":"2018","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404843"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.267"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14637"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.173"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-464503"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8511"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8164"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"issue":"22","key":"e_1_2_8_18_1","first-page":"242","article-title":"Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial)","volume":"128","author":"Sonneveld P","year":"2016","journal-title":"ASH."},{"key":"e_1_2_8_19_1","first-page":"1821","article-title":"Consolidation with Bortezomib, Lenalidomide and dexamethasone upgrades the complete remission rate after autologous hematopoietic cell transplantation in patients with multiple myeloma","volume":"130","author":"Aboudalle I","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.101"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7172"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.8541"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408898"},{"issue":"22","key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood.V128.22.1142.1142","article-title":"Frontline therapy with carfilzomib, Lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and Lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the Intergroupe Francophone Du My\u00e9Lome (IFM) Krd phase II study","volume":"128","author":"Roussel M","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.675.675"},{"key":"e_1_2_8_26_1","first-page":"3141","article-title":"Carfilzomib combined with thalidomide and low\u2010dose dexamethasone for remission induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma: the Carthadex trial","volume":"130","author":"Wester R","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_27_1","first-page":"2021","article-title":"Ixazomib\u2010Lenalidomide\u2010dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by Ixazomib maintenance is a safe and effective strategy in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe Francophone Du My\u00e9Lome (IFM)","volume":"130","author":"Moreau P","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176"},{"key":"e_1_2_8_29_1","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: an updated network meta\u2010analysis","volume":"12","author":"Mhaskar R","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403423"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq259"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.235"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01599.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28481"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4508.4508"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2014.03.005"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056747"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728220903025770"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23577"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3465-8"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T12:21:50Z","timestamp":1693916510000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/ajh.25392"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25392","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"2018-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}